Search
American Liver Foundation (ALF) applauds the Agency for Healthcare Research and Quality (AHRQ) on their groundbreaking report that assesses the prevalence of nonalcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD)*.
ALF held a Congressional briefing on Capitol Hill May 15th to discuss current dynamics around obesity and liver disease, as the prevalence of liver disease is increasing nationwide in parallel with the obesity epidemic.
Rotonya Carr, MD, FACP, Division Head of Gastroenterology at University of Washington joined us for a conversation about the changes in terminology for fatty liver disease and what this means for patients.
Rotonya Carr, MD, FACP, Division Head of Gastroenterology at University of Washington joined us for a conversation about the changes in terminology for fatty liver disease and what this means for patients.
Finding out you have non-alcoholic fatty liver disease (NAFLD) can be daunting but watch how Shawanna met the challenge head on and is reversing her diagnosis with weight loss, healthy eating and exercise!
Patients share their feelings about living with nonalcoholic fatty liver disease.
Last updated on October 11th, 2022 at 01:09 pm
See metabolic dysfunction-associated steatotic liver disease (MASLD). Medically reviewed on April 2025. Last updated on June 12th, 2025 at 01:19 pm
Steatotic Liver Disease (Fatty Liver Disease) is when excess fat is stored inside liver cells, making it harder for the liver to function.
This presentation is an excerpt from the ALF 2021 Poster Competition and showcases posters and a brief video created by early career investigators.
This presentation is an excerpt from the ALF 2021 Poster Competition and showcases posters and a brief video created by early career investigators.